T cell mediated cerebral hemorrhages and microhemorrhages during passive Aβ immunization in APPPS1 transgenic mice

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Meyer Luehmann, Melanie ^a,b,c   Mora, J Rodrigo ^a,d   Mielke, Matthew ^a   Spires Jones, Tara L ^a   De Calignon, Alix ^a   Von Andrian, Ulrich H ^d   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; IMMUNOGLOBULIN G;

ANIMAL CELL; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; CELL ACTIVITY; CELL TRANSFER; CONTROLLED STUDY; DISEASE EXACERBATION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; T LYMPHOCYTE; TRANSGENIC MOUSE; VACCINATION;

MUS MUSCULUS;

EID: 79952329934     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-22     Document Type: Article

References (41)

1. Immunotherapeutic approaches to Alzheimer's disease. A Monsonego HL Weiner, Science 2003 302 834 838 10.1126/science.1088469 14593170 (Pubitemid 37339618)
2. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. D Games D Adams R Alessandrini R Barbour P Berthelette C Blackwell T Carr J Clemens T Donaldson F Gillespie,, et al. Nature 1995 373 523 527 10.1038/373523a0 7845465
3. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. K Hsiao P Chapman S Nilsen C Eckman Y Harigaya S Younkin F Yang G Cole, Science 1996 274 99 102 10.1126/science.274.5284.99 8810256 (Pubitemid 26332733)
4. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. JL Jankowsky HH Slunt V Gonzales NA Jenkins NG Copeland DR Borchelt, Neurobiol Aging 2004 25 885 892 10.1016/j.neurobiolaging.2003.09.008 15212842 (Pubitemid 38813168)
5. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. D Schenk R Barbour W Dunn G Gordon H Grajeda T Guido K Hu J Huang K Johnson-Wood K Khan,, et al. Nature 1999 400 173 177 10.1038/22124 10408445 (Pubitemid 29327547)
6. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. F Bard C Cannon R Barbour RL Burke D Games H Grajeda T Guido K Hu J Huang K Johnson-Wood,, et al. Nat Med 2000 6 916 919 10.1038/78682 10932230 (Pubitemid 30644751)
7. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. C Janus J Pearson J McLaurin PM Mathews Y Jiang SD Schmidt MA Chishti P Horne D Heslin J French,, et al. Nature 2000 408 979 982 10.1038/35050110 11140685 (Pubitemid 32101644)
8. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. D Morgan DM Diamond PE Gottschall KE Ugen C Dickey J Hardy K Duff P Jantzen G DiCarlo D Wilcock,, et al. Nature 2000 408 982 985 10.1038/35050116 11140686 (Pubitemid 32101645)
9. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. BJ Bacskai ST Kajdasz RH Christie C Carter D Games P Seubert D Schenk BT Hyman, Nat Med 2001 7 369 372 10.1038/85525 11231639 (Pubitemid 32224356)
10. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. JC Dodart KR Bales KS Gannon SJ Greene RB DeMattos C Mathis CA DeLong S Wu X Wu DM Holtzman SM Paul, Nat Neurosci 2002 5 452 457 11941374 (Pubitemid 34454251)
11. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. JA Lombardo EA Stern ME McLellan ST Kajdasz GA Hickey BJ Bacskai BT Hyman, J Neurosci 2003 23 10879 10883 14645482 (Pubitemid 37499696)
12. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. RP Brendza BJ Bacskai JR Cirrito KA Simmons JM Skoch WE Klunk CA Mathis KR Bales SM Paul BT Hyman DM Holtzman, J Clin Invest 2005 115 428 433 15668737 (Pubitemid 40385484)
13. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. A Serrano-Pozo CM William I Ferrer E Uro-Coste MB Delisle CA Maurage C Hock RM Nitsch E Masliah JH Growdon,, et al. Brain 2010 133 1312 1327 10.1093/brain/awq056 20360050
14. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. AJ Bayer R Bullock RW Jones D Wilkinson KR Paterson L Jenkins SB Millais S Donoghue, Neurology 2005 64 94 101 15642910 (Pubitemid 40082943)
15. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. C Hock U Konietzko JR Streffer J Tracy A Signorell B Muller-Tillmanns U Lemke K Henke E Moritz E Garcia,, et al. Neuron 2003 38 547 554 10.1016/S0896-6273(03)00294-0 12765607 (Pubitemid 36645030)
16. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. JA Nicoll D Wilkinson C Holmes P Steart H Markham RO Weller, Nat Med 2003 9 448 452 10.1038/nm840 12640446 (Pubitemid 36460079)
17. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. C Holmes D Boche D Wilkinson G Yadegarfar V Hopkins A Bayer RW Jones R Bullock S Love JW Neal,, et al. Lancet 2008 372 216 223 10.1016/S0140-6736(08)61075-2 18640458 (Pubitemid 351978111)
18. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. JM Orgogozo S Gilman JF Dartigues B Laurent M Puel LC Kirby P Jouanny B Dubois L Eisner S Flitman,, et al. Neurology 2003 61 46 54 12847155 (Pubitemid 36818745)
19. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. I Ferrer M Boada Rovira ML Sanchez Guerra MJ Rey F Costa-Jussa, Brain Pathol 2004 14 11 20 10.1111/j.1750-3639.2004. tb00493.x 14997933 (Pubitemid 38200585)
20. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. S Salloway R Sperling S Gilman NC Fox K Blennow M Raskind M Sabbagh LS Honig R Doody CH van Dyck,, et al. Neurology 2009 73 2061 2070 10.1212/WNL.0b013e3181c67808 19923550
21. Bapineuzumab in Alzheimer's disease: where now? GK Wilcock, Lancet Neurol 2010 9 134 136 10.1016/S1474-4422(09)70359-X 20129159
22. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. JO Rinne DJ Brooks MN Rossor NC Fox R Bullock WE Klunk CA Mathis K Blennow J Barakos AA Okello,, et al. Lancet Neurol 2010 9 363 372 10.1016/S1474-4422(10)70043-0 20189881
23. A transgenic mouse model to analyze CD8(+) effector T cell differentiation in vivo. N Manjunath P Shankar B Stockton PD Dubey J Lieberman UH von Andrian, Proc Natl Acad Sci USA 1999 96 13932 13937 10.1073/pnas.96.24. 13932 10570176
24. Cerebral hemorrhage after passive anti-Abeta immunotherapy. M Pfeifer S Boncristiano L Bondolfi A Stalder T Deller M Staufenbiel PM Mathews M Jucker, Science 2002 298 1379 10.1126/science.1078259 12434053 (Pubitemid 35346131)
25. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. MM Racke LI Boone DL Hepburn M Parsadainian MT Bryan DK Ness KS Piroozi WH Jordan DD Brown WP Hoffman,, et al. J Neurosci 2005 25 629 636 10.1523/JNEUROSCI.4337-04.2005 15659599
26. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. DM Wilcock A Rojiani A Rosenthal S Subbarao MJ Freeman MN Gordon D Morgan, J Neuroinflammation 2004 1 24 10.1186/1742-2094-1-24 15588287
27. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. M Garcia-Alloza EM Robbins SX Zhang-Nunes SM Purcell RA Betensky S Raju C Prada SM Greenberg BJ Bacskai MP Frosch, Neurobiol Dis 2006 24 516 524 10.1016/j.nbd.2006.08.017 17029828 (Pubitemid 44716680)
28. Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. DW Ethell D Shippy C Cao JR Cracchiolo M Runfeldt B Blake GW Arendash, Neurobiol Dis 2006 23 351 361 10.1016/j.nbd.2006.03.008 16733088 (Pubitemid 44097033)
29. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. C Cao GW Arendash A Dickson MB Mamcarz X Lin DW Ethell, Neurobiol Dis 2009 34 63 70 10.1016/j.nbd.2008.12.015 19167499
30. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. JD Fryer JW Taylor RB DeMattos KR Bales SM Paul M Parsadanian DM Holtzman, J Neurosci 2003 23 7889 7896 12944519 (Pubitemid 37052357)
31. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. DT Winkler L Bondolfi MC Herzig L Jann ME Calhoun KH Wiederhold M Tolnay M Staufenbiel M Jucker, J Neurosci 2001 21 1619 1627 11222652 (Pubitemid 32182202)
32. Rebuilding an immune-mediated central nervous system disease: weighing the pathogenicity of antigen-specific versus bystander T cells. DB McGavern P Truong, J Immunol 2004 173 4779 4790 15470017 (Pubitemid 39387757)
33. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. DM Wilcock J Alamed PE Gottschall J Grimm A Rosenthal J Pons V Ronan K Symmonds MN Gordon D Morgan, J Neurosci 2006 26 5340 5346 10.1523/JNEUROSCI.0695-06.2006 16707786 (Pubitemid 44318386)
34. Random migration precedes stable target cell interactions of tumor-infiltrating T cells. P Mrass H Takano LG Ng S Daxini MO Lasaro A Iparraguirre LL Cavanagh UH von Andrian HC Ertl PG Haydon W Weninger, J Exp Med 2006 203 2749 2761 10.1084/jem.20060710 17116735 (Pubitemid 44833350)
35. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. JR Mora MR Bono N Manjunath W Weninger LL Cavanagh M Rosemblatt UH Von Andrian, Nature 2003 424 88 93 10.1038/nature01726 12840763 (Pubitemid 36834847)
36. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. WE Klunk BJ Bacskai CA Mathis ST Kajdasz ME McLellan MP Frosch ML Debnath DP Holt Y Wang BT Hyman, J Neuropathol Exp Neurol 2002 61 797 805 12230326 (Pubitemid 35001352)
37. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. BJ Bacskai ST Kajdasz ME McLellan D Games P Seubert D Schenk BT Hyman, J Neurosci 2002 22 7873 7878 12223540 (Pubitemid 35379092)
38. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. M Meyer-Luehmann TL Spires-Jones C Prada M Garcia-Alloza A de Calignon A Rozkalne J Koenigsknecht-Talboo DM Holtzman BJ Bacskai BT Hyman, Nature 2008 451 720 724 10.1038/nature06616 18256671 (Pubitemid 351220570)
39. Histotechnology. FL Carson, 2 1996
40. Microtechnical demonstration of iron. G Gomori, American Journal of Pathology 1936 12 655 663 19970292
41. The cellular reactions to experimental intracerebral hemorrhage. AH Koeppen AC Dickson JA McEvoy, J Neurol Sci 1995 134 Suppl 102 112 10.1016/0022-510X(95)00215-N 8847540